Full Text
EE344 Updated Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Therapy for Renal Cell Carcinoma After Nephrectomy in the United States

Abstract

Authors

Y Xiao AG Bensimon P Jones E Gao R Xu A Goswami R Bhattacharya

Back to Volume 27, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×